Physician profile
John W Griffin
NPI 1316940075
$1,650.87
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $474 · 2021: $258.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $442.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $332.47 | 2019-2021 | |
| Amgen INC. | $227.87 | 2019-2021 | |
| Abbvie INC. | $176.54 | 2019-2021 | |
| Genentech USA, INC. | $130.49 | 2019-2020 | |
| Pfizer INC. | $109.35 | 2019 | |
| Glaxosmithkline, LLC. | $82.81 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $69.39 | 2019 | |
| Janssen Biotech, INC. | $33.31 | 2019 | |
| Lilly USA, LLC | $17.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2020 | |
| Gilead Sciences, INC. | $11.69 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.